Genscript Bio Adds 1.53 Million New Shares in March 2026, Issued Capital Reaches 2.19 Billion

Bulletin Express04-02

Genscript Biotech Corporation filed its monthly return for the period ended 31 March 2026, detailing modest equity movements driven by employee incentive programmes.

Authorised Share Capital • Unchanged at 5.00 billion ordinary shares with a par value of USD 0.001, equivalent to authorised capital of USD 5.00 million.

Issued Share Capital • Total issued shares (excluding treasury shares) rose by 1.53 million to 2.19 billion, a 0.07 % dilution versus the February closing balance. • The company confirmed that its public float comfortably meets the Hong Kong Main Board’s minimum 25 % requirement.

Breakdown of Share Issuances 1. Share Options – 217,000 shares were issued upon option exercises under the Post-IPO Share Option Scheme, reducing outstanding options to 25.42 million. – Gross proceeds from these exercises totalled HKD 0.69 million.

2. Share Awards – 1.31 million shares were allotted for share awards granted under a scheme approved on 21 June 2024.

Other Capital Movements • No warrants, convertibles, share repurchases or treasury-share transfers occurred during the month.

With the latest allotments, Genscript Bio’s issued share base stands at 2.19 billion shares, while authorised capacity remains ample at 5.00 billion shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1173846630?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-02 16:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173846630","market":"us","top_or_hot":-1,"title":"Genscript Bio Adds 1.53 Million New Shares in March 2026, Issued Capital Reaches 2.19 Billion","media":"Bulletin Express","content":"<p>Genscript Biotech Corporation filed its monthly return for the period ended 31 March 2026, detailing modest equity movements driven by employee incentive programmes.</p>\n<p>Authorised Share Capital  \n• Unchanged at 5.00 billion ordinary shares with a par value of USD 0.001, equivalent to authorised capital of USD 5.00 million.</p>\n<p>Issued Share Capital  \n• Total issued shares (excluding treasury shares) rose by 1.53 million to 2.19 billion, a 0.07 % dilution versus the February closing balance.  \n• The company confirmed that its public float comfortably meets the Hong Kong Main Board’s minimum 25 % requirement.</p>\n<p>Breakdown of Share Issuances  \n1. Share Options  \n   – 217,000 shares were issued upon option exercises under the Post-IPO Share Option Scheme, reducing outstanding options to 25.42 million.  \n   – Gross proceeds from these exercises totalled HKD 0.69 million.</p>\n<p>2. Share Awards  \n   – 1.31 million shares were allotted for share awards granted under a scheme approved on 21 June 2024.</p>\n<p>Other Capital Movements  \n• No warrants, convertibles, share repurchases or treasury-share transfers occurred during the month.</p>\n<p>With the latest allotments, Genscript Bio’s issued share base stands at 2.19 billion shares, while authorised capacity remains ample at 5.00 billion shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genscript Bio Adds 1.53 Million New Shares in March 2026, Issued Capital Reaches 2.19 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenscript Bio Adds 1.53 Million New Shares in March 2026, Issued Capital Reaches 2.19 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-02 16:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Genscript Biotech Corporation filed its monthly return for the period ended 31 March 2026, detailing modest equity movements driven by employee incentive programmes.</p>\n<p>Authorised Share Capital  \n• Unchanged at 5.00 billion ordinary shares with a par value of USD 0.001, equivalent to authorised capital of USD 5.00 million.</p>\n<p>Issued Share Capital  \n• Total issued shares (excluding treasury shares) rose by 1.53 million to 2.19 billion, a 0.07 % dilution versus the February closing balance.  \n• The company confirmed that its public float comfortably meets the Hong Kong Main Board’s minimum 25 % requirement.</p>\n<p>Breakdown of Share Issuances  \n1. Share Options  \n   – 217,000 shares were issued upon option exercises under the Post-IPO Share Option Scheme, reducing outstanding options to 25.42 million.  \n   – Gross proceeds from these exercises totalled HKD 0.69 million.</p>\n<p>2. Share Awards  \n   – 1.31 million shares were allotted for share awards granted under a scheme approved on 21 June 2024.</p>\n<p>Other Capital Movements  \n• No warrants, convertibles, share repurchases or treasury-share transfers occurred during the month.</p>\n<p>With the latest allotments, Genscript Bio’s issued share base stands at 2.19 billion shares, while authorised capacity remains ample at 5.00 billion shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1173846630","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173846630","pubTimestamp":1775119465,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Genscript Biotech Corporation filed its monthly return for the period ended 31 March 2026, detailing modest equity movements driven by employee incentive programmes. Authorised Share Capital   •...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"金斯瑞生物2026年3月新增153万股已发行股本达21.9亿","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"Genscript Biotech Corporation filed its monthly return for the period ended 31 March 2026, detailing modest equity movements driven by employee incentive programmes.\nAuthorised Share Capital  \n• Unchanged at 5.00 billion ordinary shares with a par value of USD 0.001, equivalent to authorised capital of USD 5.00 million.\nIssued Share Capital  \n• Total issued shares (excluding treasury shares) rose by 1.53 million to 2.19 billion, a 0.07 % dilution versus the February closing balance.  \n• The company confirmed that its public float comfortably meets the Hong Kong Main Board’s minimum 25 % requirement.\nBreakdown of Share Issuances  \n1. Share Options  \n   – 217,000 shares were issued upon option exercises under the Post-IPO Share Option Scheme, reducing outstanding options to 25.42 million.  \n   – Gross proceeds from these exercises totalled HKD 0.69 million.\n2. Share Awards  \n   – 1.31 million shares were allotted for share awards granted under a scheme approved on 21 June 2024.\nOther Capital Movements  \n• No warrants, convertibles, share repurchases or treasury-share transfers occurred during the month.\nWith the latest allotments, Genscript Bio’s issued share base stands at 2.19 billion shares, while authorised capacity remains ample at 5.00 billion shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173846630","isCrawlerRequest":true}